Innovating Works

HYPOXIMMUNO

Financiado
Tackling the Achilles Heel of Immunotherapy Validating imaging biomarkers and t...
Tackling the Achilles Heel of Immunotherapy Validating imaging biomarkers and targeting the immunological niche of tumour hypoxia Lung cancer is the most common cause of death from cancer worldwide with 1.59 million deaths annually and it places the highest economic burden of all cancers on the EU at €18.8billion. These figures call for a major transformatio... Lung cancer is the most common cause of death from cancer worldwide with 1.59 million deaths annually and it places the highest economic burden of all cancers on the EU at €18.8billion. These figures call for a major transformation of the therapeutic management of lung cancer. The recent developments in immunotherapy give new hope. At present a significant minority of patients benefit from immune therapy, which remains not curative when delivered alone. It is thus clear that improving the efficacy of immune therapy is needed as well as the identification of predictive biomarkers. Combining immunotherapy with radiotherapy improves effectiveness, but resistance is still common, most probably because of hypoxia. In HYPOXIMMUNO, we will open up a new paradigm in treating metastatic NSCLC. I will provide for the first time (pre)clinical proof of concept of (i) highly innovative CT-based radiomics and PET-hypoxia imaging patient stratification tools and (ii) a tri-modal curative hypoxia-targeting treatment strategy that complements current immunotherapy and radiotherapy approaches. This tri-modal curative treatment strategy is based on (1) high precision Stereotactic Radiotherapy (SABR) to kill cancer cells and trigger the immune system, combined with (2) a hypoxia-activated prodrug to target the hypoxic tumour cells resistant to immunotherapy and (3) a promising and innovative tumour specific antibody (Ab)-based immunotherapy (immunocytokine L19-IL2 to push the accelerator with or without a checkpoint inhibitor to release the break) to form a powerful synergistic immuno-oncology strategy. In HYPOXIMMUNO, I envision to lay the foundation for the next breakthrough in oncology, by improving patient selection and developing highly innovative cancer therapies that target hypoxia, to improve the quality of life and prolong survival of cancer patients, in particular patients with metastatic NSCLC (watch the animation summarising the project: https://youtu.be/oP9Gp4a0b_Q). ver más
31/05/2023
UNIVERSITEIT MAAST...
2M€
Duración del proyecto: 78 meses Fecha Inicio: 2016-11-30
Fecha Fin: 2023-05-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2023-05-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-ADG-2015: ERC Advanced Grant
Cerrada hace 9 años
Presupuesto El presupuesto total del proyecto asciende a 2M€
Líder del proyecto
UNIVERSITEIT MAASTRICHT No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5